Business Context and Reporting Period
This Form 6-K filing is submitted by pSivida Limited, a foreign issuer, for the month of October 2006. The report was signed on October 10, 2006, by Aaron Finlay, the Company Secretary. The registrant files annual reports under Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of a specific corporate event rather than a financial statement.
Material Changes and Corporate Events
- Clinical Trial Milestone: The primary purpose of this filing is to announce that the first patient has been implanted in the European Pancreatic Cancer Study (Exhibit 99.1).
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, or a detailed discussion of risks and contingencies beyond the announcement of the clinical study milestone.
Investor Verification Checklist
- Verify the status and protocol details of the European Pancreatic Cancer Study referenced in Exhibit 99.1.
- Confirm the identity of the first patient implanted and the location of the study site.
- Review subsequent filings for updates on the study's progress and any resulting financial impacts.